STAT+: Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation

negativeNegative

AI Analysis

Summary

Novo Nordisk has discontinued two cardiovascular trials of an anti-inflammatory drug, representing a setback for the inflammation-targeting therapeutic approach.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Two cardiovascular trials stopped

Importance:6/10

Sentiment:

-0.80

clinical_trial_terminationcardiovascularinflammationdrug_development

Related Companies

$NVO

Read the original article

Published by STAT News on September 7, 2026 11:13 AM

Read Original